References
1. Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for
multiple sclerosis. Vol. 26, Multiple Sclerosis Journal. SAGE
Publications Ltd; 2020. p. 137–52.
2. Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J,
Frisell T, et al. Comparative effectiveness of rituximab and other
initial treatment choices for multiple sclerosis. JAMA Neurol.
2018;75(3):320–7.
3. Kidoguchi K, Kubota Y, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka
A, et al. Severe infusion reaction, anti-rituximab antibodies and
lymphoma Learning points for clinicians.
4. Vedala K, Desikan SP, McClain C, Jacob D, Desikan R. Capillary Leak
Syndrome From Rituximab Therapy of Lymphoma. J Investig Med High Impact
Case Rep. 2020;8.
5. Baker D, Ali L, Saxena G, Pryce G, Jones M, Schmierer K, et al. The
Irony of Humanization: Alemtuzumab, the First, But One of the Most
Immunogenic, Humanized Monoclonal Antibodies. Front Immunol. 2020 Feb
14;11:124.
6. Amlani A, Barber C, Fifi-Mah A, Monzon J. Successful Treatment of
Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning
from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review
of Literature. The Oncologist. 2020;25:1120–3.
7. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen
Receptor T Cell Therapy. Vol. 25, Biology of Blood and Marrow
Transplantation. Elsevier Inc.; 2019. p. e123–7.
8. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor
and Cytokine Release Syndrome. Immunity. 2020 May 19;52(5):731–3.
9. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA
Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor
T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome. The
Oncologist. 2018 Aug;23(8):943–7.
10. Chavez JC, Jain MD, Kharfan-Dabaja MA. Cytokine release syndrome and
neurologic toxicities associated with chimeric antigen receptor T-cell
therapy: A comprehensive review of emerging grading models. Vol. 13,
Hematology/ Oncology and Stem Cell Therapy. King Faisal Specialist
Hospital and Research Centre; 2020. p. 1–6.
11. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A,
Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28
monoclonal antibody TGN1412. N Engl J Med. 2006 Sep 7;355(10):1018–28.
12. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR,
et al. Rituximab-induced serum sickness in multiple sclerosis patients.
Mult Scler Relat Disord. 2019;36:101402.
13. Fuentes Fernandez I, Hernandez-Clares R, Carreón Guarnizo E, Meca
Lallana JE. Capillary leak syndrome in neuromyelitis optica treated with
rituximab. Mult Scler Relat Disord. 2017;16:22–3.
Figure legends :
Figure 1; Fluid-attenuated inversion recovery (FLAIR) cervical spine MRI
of the patient revealing a hyperintense lesion at the level of C3-C4.